review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Yelin E | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | rheumatoid arthritis | Q187255 |
P304 | page(s) | 47-51 | |
P577 | publication date | 1996-03-01 | |
P1433 | published in | The Journal of rheumatology. Supplement | Q27711737 |
P1476 | title | The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates | |
P478 | volume | 44 |
Q50688343 | A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. |
Q35240630 | A multicenter clinical trial in rheumatoid arthritis comparing silicone metacarpophalangeal joint arthroplasty with medical treatment |
Q34398912 | A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings |
Q92188732 | Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania |
Q36555104 | Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. |
Q35550292 | Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients |
Q35780338 | Epidemiology and burden of illness of rheumatoid arthritis |
Q34896078 | Epstein-Barr virus and rheumatoid arthritis: is there a link? |
Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
Q36843031 | Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. |
Q43492890 | Health-related quality of life in young adult patients with rheumatoid arthritis in Iran: reliability and validity of the Persian translation of the PedsQL™ 4.0 Generic Core Scales Young Adult Version. |
Q35059538 | Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease? |
Q37172804 | Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group |
Q40905089 | Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries |
Q36100671 | International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review |
Q31019080 | Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. |
Q35555089 | Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity |
Q42360360 | Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam |
Q81478994 | The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis |
Q53854537 | The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. |
Q58025187 | The economic burden of rheumatoid arthritis: beyond health care costs |
Q37251489 | The impact of rheumatoid arthritis and biologics on employers and payers. |
Search more.